Elizabeth Anne Noonan, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1515 W Pleasant St, Knoxville, IA 50138 Phone: 641-842-3101 Fax: 641-828-6788 |
Elizabeth Ann Schneider, PTMS Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1008 W Bell Ave, Suite 105, Knoxville, IA 50138 Phone: 641-828-7211 Fax: 641-842-3791 |
Jacob Lincoln Stearns, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1002 S Lincoln St, Knoxville, IA 50138 Phone: 641-842-1464 Fax: 641-842-1478 |
John Scott Evans, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1008 W Bell Ave, Suite 105, Knoxville, IA 50138 Phone: 641-828-7211 Fax: 641-842-3791 |
Sarah Thompson Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1002 S Lincoln St, Knoxville, IA 50138 Phone: 641-842-1464 |
Nicole M Henderson, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 606 N 7th St, Knoxville, IA 50138 Phone: 641-842-2187 |
Addison Duane Collard, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1607 N Lincoln St, Knoxville, IA 50138 Phone: 641-828-5019 |
Jessica Stickel Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1002 S Lincoln St, Knoxville, IA 50138 Phone: 641-842-1464 |
Jerry Leonard Rooney, PHYSICAL THERAPIST Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1002 S Lincoln, Knoxville, IA 50138 Phone: 641-842-2151 Fax: 641-842-1481 |
Susan Marie Woodle, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1008 W Bell Ave, Suite 105, Knoxville, IA 50138 Phone: 641-828-7211 Fax: 641-842-3791 |
News Archive
A new study published on the preprint server bioRxiv* in August 2020 shows that the man-made compound silicon nitride, which is used in medical implants and high mechanical performance engineering applications, is capable of inactivating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at varying concentrations without causing cell cytotoxicity. This finding should be investigated to develop disinfectants to clear the virus from surfaces, preventing its spread.
The Prostate Cancer Foundation (PCF) has announced that more than 200 new therapies are being developed for prostate cancer, many by researchers supported by the PCF. Substantially more prostate cancer therapies are in later stages of clinical development (Phases II and III) than ever before.
Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking GleevecĀ® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.
ActiveSite Pharmaceuticals, Inc., announced today the online publication of a study in the journal Diabetes that describes the effectiveness of its novel plasma kallikrein inhibitor ASP-440 in reducing blood-retinal barrier breakdown in a rodent model of diabetes.
› Verified 2 days ago